Articles published by Biocept, Inc.

< Previous 1 2 Next >

Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

May 16, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 08, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Reports 2021 Fourth Quarter and Full Year Financial Results

April 06, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance

March 31, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022

March 18, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer

February 22, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer

February 16, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

February 10, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant

January 21, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10

January 04, 2022

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

December 09, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

November 22, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer

November 18, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer

November 18, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Reports Third Quarter 2021 Financial Results

November 15, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations

November 09, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021

November 08, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept to Present at the LD Micro Main Event on October 13

October 06, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic

September 22, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 31, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

August 19, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Reports Second Quarter 2021 Financial Results

August 16, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021

August 09, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

July 21, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman

July 20, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept to Participate in Two July Investment Conferences

July 19, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers

July 06, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept Joins the Russell Microcap® Index

June 28, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer

June 22, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC DGX

Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service

June 15, 2021

From Biocept, Inc.

Via Business Wire

Tickers BIOC

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.